Acylated- and unacylated ghrelin during an oral glucose tolerance test in humans at risk for type 2 diabetes mellitus
Authors' conclusion
Our data demonstrate lower concentrations for both AcG and UnG with increasing BMI as well as an increased proportion of the biologically active, acylated form of ghrelin giving point to pharmacologic intervention in ghrelin acylation and/or increase in UnG for treatment of obesity despite decreased absolute AcG levels.
Study context
- Population
- Humans at risk for T2D, cohort covering a broad range of BMI (17.95 kg/m²-76.25 kg/m²)245 with OGTT
- Participants
- 545 participants
- Outcome
- Relation of acylated (AcG) and unacylated ghrelin (UnG) with body weight and insulin resistance, fasting and post-OGTT
Methodological detailsmetabolically well characterized cohort
- Metabolically well characterized cohort
Main finding
As reported in the abstract
Fasting AcG, UnG and AcG/UnG ratio vs BMI
- Fasting AcG, median
- 94.2 pg/ml
- Fasting unacylated ghrelin (UnG), median
- 175.3 pg/ml
- AcG and UnG negatively, AcG/UnG ratio positively correlated with BMI
- all p < 0.0001
- Insulin sensitivity (ISI) correlated positively with AcG
- p = 0.0014
- ISI correlated positively with UnG
- p = 0.0004
Observational data: associations, not effects.
Further findings
AcG and UnG after OGTT · 30 min; 90-120 min
- Significant changes: slight decreases after 30 min, increases after 90-120 min
AcG increase by BMI-divergent groups
- More pronounced AcG increases in the two groups with BMI < 40 kg/m²
Original publication
Acylated- and unacylated ghrelin during an oral glucose tolerance test in humans at risk for type 2 diabetes mellitus. Int J Obes (Lond). Published 7 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →